Idiopathic pulmonary fibrosis (IPF) is a deadly disease, largely unresponsive to treatment
with corticosteroids and immunosuppressives. The aim of this randomized, prospective …

In a recent study of IFN-γ 1b in 330 patients with idiopathic pulmonary fibrosis (IPF),
progression-free survival was unchanged; however, a trend toward lower mortality was seen …

Although most evident in the skin, the process of scarring, or fibrosis, occurs in all major
organs because of impaired epithelial self‐renewal. No current therapy exists for Idiopathic …

Modulation of cytokine expression represents a potentially useful approach for the treatment
of idiopathic pulmonary fibrosis (IPF). To identify potential targets for such intervention, semi …

OBJECTIVE: Transforming growth factor β1 (TGF-β1) is one of the key profibrotic mediators
in the pathogenesis of idiopathic pulmonary fibrosis (IPF). The purpose of this study was to …

Idiopathic pulmonary fibrosis (IPF) is characterized by progressive fibroblast and
myofibroblast proliferation, and extensive deposition of extracellular matrix (ECM). Fibroblast …

EGCG and Pulmonary Fibrosis Nine patients who were scheduled to undergo lung biopsy
for pulmonary fibrosis were given epigallocatechin gallate (EGCG) for 2 weeks. Levels of …

Pathogenic fibrotic diseases, including Idiopathic Pulmonary Fibrosis (IPF), have some of
the worst prognoses and affect millions of people worldwide. With unclear etiology and …

Objective To identify the role of cytokines involved in the development of lung fibrosis in
patients with idiopathic pulmonary fibrosis (IPF). Methods Proteins and gene expression of …

Idiopathic pulmonary fibrosis (IPF) is a lung disease that is characterized by epithelial cell
damage and areas of denuded basement membrane resulting in inflammation, fibroblast …